Press "Enter" to skip to content

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound – Valdosta Daily Times

admin 0

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound  Valdosta Daily Times

INGELHEIM, Germany & MUMBAI, India–(BUSINESS WIRE)–Sep 4, 2019–. Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, …

“colorectal cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *